The Effect of Empagliflozin On Cardiac Systolic and Diastolic Functions In Patients With Type 2 Diabetes Mellitus and Hypertension
Eastern Journal of Medicine, cilt.30, sa.3, ss.388-396, 2025 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 30 Sayı: 3
- Basım Tarihi: 2025
- Doi Numarası: 10.5505/ejm.2025.04378
- Dergi Adı: Eastern Journal of Medicine
- Derginin Tarandığı İndeksler: Scopus, EMBASE, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.388-396
- Anahtar Kelimeler: Empagliflozin, global longitudinal strain, Left atrial volume index, sodium glucose co-transporter-2 inhibitor
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Empagliflozin may positively affect subclinical left ventricle (LV) dysfunction. We aimed to investigate the effect of empagliflozin on cardiac systolic and diastolic functions in patients with Type 2 diabetes mellitus (DM) and hypertension. Sixty-three patients who underwent transthoracic echocardiography between October-2019 and June-2020, receiving at least one antihypertensive pill, and started empagliflozin treatment due to Type-2 DM were included in the study. Echocardiographic parameters like global longitudinal strain (GLS), left atrial volume index (Lavi), before and 6 months after empagliflozin treatment were compared. Patient's blood pressure (BP), waist circumference, body mass index (BMI), NT-proBNP and other blood parameters were examined. Of the 63 patients who participated in the study, 30 (47.6%) were male. There was an improvement in subclinical cardiac dysfunctions with the use of empagliflozin for 6 months. There was statistically significant difference in GLS (15±2.42 to 16.3±2.3, p<0.001), E/e’ (10[8.5-11], 10.5[9-12], p:0.01), Lavi (29.6±10.5to 27.3±9.8,p<0.001) and NT-proBNP (75,65.7,p<0.001). Significant improvement in GLS was associated with baseline BMI and NT-proBNP elevation. Also, the decrease in Lavi was found to be related to the initial NT-proBNP elevation. In addition, there were significant changes in patients BP (135±7.9, 128±6.9, p-<0.001), diastolic BP (80.2±7.2, 78.6±6.6, p-value 0.012), waist circumference (107±8.9, 104±9.1,p<0.001) and BMI (33.5±5.6;30.2±4.3;p<0.001). Empagliflozin treatment improved subclinical LV systolic and diastolic dysfunctions in patients with Type 2 DM and hypertension. The benefit of Empagliflozin may be associated with weight loss and decrease of NT-pro BNP as this improvement was more prominent in patients with high baseline BMI and NT-proBNP.